Lycium barbarum polysaccharide attenuates cisplatininduced apoptosis in ovary granulosa cells via alleviation of endoplasmic reticulum stress
Purpose: To investigate the effect of Lycium barbarum polysaccharide (LBP) on apoptosis of ovary granulose cells (GCs), as well as its underlying mechanism.
Methods: GCs were isolated from Sprague Dawley (SD) rats and divided into three groups: control group, model group (DDP) and LBP group. Cell morphology was observed by H & E staining under optical microscope. Expression of follicle stimulating hormone receptor (FSHR) was assessed by immunohistochemistry (IHC), while cell viability was assayed using 3-(4,5-dimethyl-2-thiazolyl)-2,5- diphenyl-2-H-tetrazolium bromide (MTT). Apoptosis was determined by flow cytometry. Expressions of glucose-regulated protein 78(GRP78), C/EBP homologous protein (CHOP), caspase-3, Bax protein and B cell lymphoma-2(Bcl-2) were assayed by Western blot and qRT-PCR.
Results: Apoptosis index (37.6 ± 2.44 %) was significantly higher (p > 0.05) in DDP group than in the control group (14.3 ± 1.09 %), while mRNA levels and expressions of caspase-3, Bcl-2 and Bax increased significantly (p > 0.05). Expressions of GRP78 and CHOP in the DDP group were also higher than in the control group (p > 0.05). However, these effects were effectively blocked by co-incubation with LBP. Moreover, the DDP-induced increase in apoptosis index was dose-dependently and significantly lowered by LBP (p > 0.05).
Conclusion: LBP exerts protective effect on cisplatin-induced apoptosis in ovary granulosa cells by alleviating endoplasmic reticulum stress and regulating levels of apoptosis-related proteins. Thus, LBP has the potential for alleviating adverse effects induced by cisplatin in the treatment of ovary granulosa lesions.
Keywords: Cis-platin, Ovary granulosa lesions, Lycium barbarum polysaccharide, Endoplasmic reticulum stress, Apoptosis
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.